InDex Pharmaceuticals Holding AB engages in the development of drugs for the treatment of diseases such as inflammation and cancer. It conducts research, technology development, and commercialization of scientific discoveries in the biomedical field. The firm also develops a platform of patent-protected substances, so-called deoxyribonucleic acid-based ImmunModulatory Sequences, with the potential to be used for the treatment of various immunological diseases. The company was founded by Oliver von Stein and Svante Rasmuson in 2000 and is headquartered in Stockholm, Sweden.